中国医药：关于子公司获得药品补充申请批准通知书的公告

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplemental applications for injectable L-lysine, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] - The injectable L-lysine is expected to contribute positively to the company's revenue stream following its market introduction [1] - The successful completion of the consistency evaluation indicates the company's commitment to maintaining high-quality standards in its pharmaceutical offerings [1]